Cargando…

The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease

BACKGROUND: Parkinson’s disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shengdi, Chan, Piu, Sun, Shenggang, Chen, Haibo, Zhang, Baorong, Le, Weidong, Liu, Chunfeng, Peng, Guoguang, Tang, Beisha, Wang, Lijuan, Cheng, Yan, Shao, Ming, Liu, Zhenguo, Wang, Zhenfu, Chen, Xiaochun, Wang, Mingwei, Wan, Xinhua, Shang, Huifang, Liu, Yiming, Xu, Pingyi, Wang, Jian, Feng, Tao, Chen, Xianwen, Hu, Xingyue, Xie, Anmu, Xiao, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928283/
https://www.ncbi.nlm.nih.gov/pubmed/27366321
http://dx.doi.org/10.1186/s40035-016-0059-z
_version_ 1782440408769363968
author Chen, Shengdi
Chan, Piu
Sun, Shenggang
Chen, Haibo
Zhang, Baorong
Le, Weidong
Liu, Chunfeng
Peng, Guoguang
Tang, Beisha
Wang, Lijuan
Cheng, Yan
Shao, Ming
Liu, Zhenguo
Wang, Zhenfu
Chen, Xiaochun
Wang, Mingwei
Wan, Xinhua
Shang, Huifang
Liu, Yiming
Xu, Pingyi
Wang, Jian
Feng, Tao
Chen, Xianwen
Hu, Xingyue
Xie, Anmu
Xiao, Qin
author_facet Chen, Shengdi
Chan, Piu
Sun, Shenggang
Chen, Haibo
Zhang, Baorong
Le, Weidong
Liu, Chunfeng
Peng, Guoguang
Tang, Beisha
Wang, Lijuan
Cheng, Yan
Shao, Ming
Liu, Zhenguo
Wang, Zhenfu
Chen, Xiaochun
Wang, Mingwei
Wan, Xinhua
Shang, Huifang
Liu, Yiming
Xu, Pingyi
Wang, Jian
Feng, Tao
Chen, Xianwen
Hu, Xingyue
Xie, Anmu
Xiao, Qin
author_sort Chen, Shengdi
collection PubMed
description BACKGROUND: Parkinson’s disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson’s Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved. OBJECTIVES: To update the treatment guidelines based on current foreign and domestic practice guidelines and clinical evidence, and to improve the treatment options available to physicians in the management of PD. SUMMARY: A variety of treatment recommendations in the treatment guidelines have been proposed, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications. Moreover, different treatment strategies should be considered at different stages of the disease. Importantly, treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China.
format Online
Article
Text
id pubmed-4928283
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49282832016-06-30 The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease Chen, Shengdi Chan, Piu Sun, Shenggang Chen, Haibo Zhang, Baorong Le, Weidong Liu, Chunfeng Peng, Guoguang Tang, Beisha Wang, Lijuan Cheng, Yan Shao, Ming Liu, Zhenguo Wang, Zhenfu Chen, Xiaochun Wang, Mingwei Wan, Xinhua Shang, Huifang Liu, Yiming Xu, Pingyi Wang, Jian Feng, Tao Chen, Xianwen Hu, Xingyue Xie, Anmu Xiao, Qin Transl Neurodegener Review BACKGROUND: Parkinson’s disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson’s Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved. OBJECTIVES: To update the treatment guidelines based on current foreign and domestic practice guidelines and clinical evidence, and to improve the treatment options available to physicians in the management of PD. SUMMARY: A variety of treatment recommendations in the treatment guidelines have been proposed, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications. Moreover, different treatment strategies should be considered at different stages of the disease. Importantly, treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China. BioMed Central 2016-06-30 /pmc/articles/PMC4928283/ /pubmed/27366321 http://dx.doi.org/10.1186/s40035-016-0059-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Chen, Shengdi
Chan, Piu
Sun, Shenggang
Chen, Haibo
Zhang, Baorong
Le, Weidong
Liu, Chunfeng
Peng, Guoguang
Tang, Beisha
Wang, Lijuan
Cheng, Yan
Shao, Ming
Liu, Zhenguo
Wang, Zhenfu
Chen, Xiaochun
Wang, Mingwei
Wan, Xinhua
Shang, Huifang
Liu, Yiming
Xu, Pingyi
Wang, Jian
Feng, Tao
Chen, Xianwen
Hu, Xingyue
Xie, Anmu
Xiao, Qin
The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
title The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
title_full The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
title_fullStr The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
title_full_unstemmed The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
title_short The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
title_sort recommendations of chinese parkinson’s disease and movement disorder society consensus on therapeutic management of parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928283/
https://www.ncbi.nlm.nih.gov/pubmed/27366321
http://dx.doi.org/10.1186/s40035-016-0059-z
work_keys_str_mv AT chenshengdi therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chanpiu therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT sunshenggang therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chenhaibo therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT zhangbaorong therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT leweidong therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT liuchunfeng therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT pengguoguang therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT tangbeisha therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wanglijuan therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chengyan therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT shaoming therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT liuzhenguo therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wangzhenfu therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chenxiaochun therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wangmingwei therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wanxinhua therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT shanghuifang therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT liuyiming therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT xupingyi therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wangjian therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT fengtao therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chenxianwen therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT huxingyue therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT xieanmu therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT xiaoqin therecommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chenshengdi recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chanpiu recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT sunshenggang recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chenhaibo recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT zhangbaorong recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT leweidong recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT liuchunfeng recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT pengguoguang recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT tangbeisha recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wanglijuan recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chengyan recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT shaoming recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT liuzhenguo recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wangzhenfu recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chenxiaochun recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wangmingwei recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wanxinhua recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT shanghuifang recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT liuyiming recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT xupingyi recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT wangjian recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT fengtao recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT chenxianwen recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT huxingyue recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT xieanmu recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease
AT xiaoqin recommendationsofchineseparkinsonsdiseaseandmovementdisordersocietyconsensusontherapeuticmanagementofparkinsonsdisease